A Phase 1 interventional study of rhuMAb 2C4 in Neoplasms, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-27.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without causing severe side effects. All study participants will be assigned to specific group to evaluate different dosages of rhuMAb 2C4. The study is scheduled to run for up to one year depending on how patients respond to the study treatment.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 21 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death
For this protocol, an AE is defined any untoward medical occurrence (e.g., sign, symptom, disease, syndrome, intercurrent illness, abnormal laboratory finding) that emerges or worsens relative to pretreatment baseline during the treatment or post-treatment periods, regardless of the suspected cause. For this protocol an SAE was defined as any AE that occurred at any dose if: * It resulted in death (i.e., the AE caused or led to death), * It was life threatening, * It required or prolonged inpatient hospitalization, * It was disabling, * It resulted in a congenital anomaly/birth defect, * It may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the outcomes listed above. The primary cause of death for all reported cases was disease progression, and all of the deaths occurred following study discontinuation, with one death occurring within 4 weeks of the last treatment day.
Time frame: Days 1, 2, 5, 8, and 15 of Cycle 1; Days 1, 8, and Week 3, of Cycles 2 and beyond up to 1 year and at the follow-up visit (4 weeks after last infusion)
Number of Participants With Dose-Limiting Toxicities (DLTs)
Incidence of DLTs defined as any Grade 3 or 4 major organ toxicity according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2 or any subjectively intolerable toxicity felt by the investigator to be related to rhuMAb 2C4. One participant in the 15.0 mg/kg dose group experienced a gastrointestinal hemorrhage on Day 16. This event was judged by the investigator to be related to study drug. The participant recovered in 3 days and continued to receive rhuMAb 2C4 beyond Cycle 2.This was the only DLT reported during the first two treatment cycles.
Time frame: Day 1 of Cycles 1 and 2, and 24 hours after Cycle 2 infusion
Pharmacokinetic Measurement of Area Under the Curve (AUC)
Mean rhuMAb 2C4 serum concentrations versus nominal time profiles for the first two treatment cycles are presented for AUC micrograms per milliliters (ug/mL) by day. A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes following start of infusion and at 1.5, 4, and 8 hours postdose) 2, 5, 8 and 15 of Cycle 1; Days 1 (predose and 29 minutes following start of infusion) and 8 of Cycle 2
Pharmacokinetic Measurement of Systemic Clearance (CL)
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Pharmacokinetic Measurement of Volume of Central Compartment (Vc)
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Pharmacokinetic Measurement of Steady-State Volume of Distribution (Vss)
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Pharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial)
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Pharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
| Milestone | rhuMAb 2C4: 0.5 Milligrams Per Kilogram (mg/kg) | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 8 |
| Discontinued before 2 treatment cycles | 0 | 0 | 1 | 0 | 1 |
| Completed 2 cycles of treatment | 3 | 3 | 3 | 3 | 7 |
| Discontinued at cycle 2 | 2 | 2 | 1 | 1 | 3 |
| Treated beyond cycle 2 | 1 | 1 | 2 | 2 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 4 | 3 | 8 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Admitted for signs of pd | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Clinical symptoms progression not pd | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pd requiring surgery | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision due to pd | 2 | 3 | 2 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
For this protocol, an AE is defined any untoward medical occurrence (e.g., sign, symptom, disease, syndrome, intercurrent illness, abnormal laboratory finding) that emerges or worsens relative to pretreatment baseline during the treatment or post-treatment periods, regardless of the suspected cause. For this protocol an SAE was defined as any AE that occurred at any dose if: * It resulted in death (i.e., the AE caused or led to death), * It was life threatening, * It required or prolonged inpatient hospitalization, * It was disabling, * It resulted in a congenital anomaly/birth defect, * It may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the outcomes listed above. The primary cause of death for all reported cases was disease progression, and all of the deaths occurred following study discontinuation, with one death occurring within 4 weeks of the last treatment day.
| participants | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Adverse events | 3 | 3 | 4 | 3 | 8 |
| Serious adverse events | 3 | 1 | 2 | 0 | 5 |
| Death | 3 | 1 | 2 | 0 | 1 |
Incidence of DLTs defined as any Grade 3 or 4 major organ toxicity according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2 or any subjectively intolerable toxicity felt by the investigator to be related to rhuMAb 2C4. One participant in the 15.0 mg/kg dose group experienced a gastrointestinal hemorrhage on Day 16. This event was judged by the investigator to be related to study drug. The participant recovered in 3 days and continued to receive rhuMAb 2C4 beyond Cycle 2.This was the only DLT reported during the first two treatment cycles.
| participants | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) | 3 | 1 | 2 | 0 | 6 |
Mean rhuMAb 2C4 serum concentrations versus nominal time profiles for the first two treatment cycles are presented for AUC micrograms per milliliters (ug/mL) by day. A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| ug*hr/mL | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetic Measurement of Area Under the Curve (AUC) | 43.057 ± 17.770 | 569.433 ± 168.995 | 1478.000 ± 349.396 | 3959.333 ± 1110.113 | 4502.625 ± 1245.289 |
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| mL/day/kg | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetic Measurement of Systemic Clearance (CL) | 13.1 ± 5.5 | 3.74 ± 1.28 | 3.52 ± 0.85 | 2.69 ± 0.92 | 3.68 ± 1.47 |
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| mL/kg | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetic Measurement of Volume of Central Compartment (Vc) | 43.6 ± 4.6 | 35.5 ± 3.5 | 39.7 ± 6.2 | 38.4 ± 5.3 | 42.8 ± 7.9 |
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| mL/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|
| Pharmacokinetic Measurement of Steady-State Volume of Distribution (Vss) | 69.5 ± 13.7 | 74.1 ± 30.4 | 73.4 ± 13.6 | 85.3 ± 36.7 |
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| days | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|
| Pharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial) | 0.96 ± 0.99 | 1.09 ± 0.74 | 1.23 ± 0.90 | 1.50 ± 1.17 |
A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.
| days | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days | 2.6 ± 0.9 | 14.9 ± 1.1 | 17.2 ± 10.3 | 22.3 ± 9.9 | 18.6 ± 8.8 |
Collected over From baseline through 4 weeks after the last infusion of study drug, up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rhuMAb 2C4: 0.5 mg/kg | — | 3/3 (100%) | 3/3 (100%) |
| rhuMAb 2C4: 2 mg/kg | — | 1/3 (33.3%) | 3/3 (100%) |
| rhuMAb 2C4: 5 mg/kg | — | 2/4 (50%) | 4/4 (100%) |
| rhuMAb 2C4: 10 mg/kg | — | 0/3 (0%) | 3/3 (100%) |
| rhuMAb 2C4: 15 mg/kg | — | 5/8 (62.5%) | 8/8 (100%) |
| Event | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/4 | 0/3 | 1/8 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 |
| Supraventricular tachycardiaCardiac disorders | 0/3 | 1/3 | 0/4 | 0/3 | 0/8 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 |
| Ureteric stenosisRenal and urinary disorders | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 |
| Jugular vein thrombosisVascular disorders | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 |
| DepressionPsychiatric disorders | 0/3 | 0/3 | 1/4 | 0/3 | 0/8 |
| Mental status changesPsychiatric disorders | 0/3 | 0/3 | 1/4 | 0/3 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 0/4 | 0/3 | 1/8 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/4 | 0/3 | 1/8 |
| Event | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 3/3 | 1/3 | 4/4 | 0/3 | 3/8 |
| NauseaGastrointestinal disorders | 3/3 | 1/3 | 2/4 | 2/3 | 2/8 |
| FatigueGeneral disorders | 3/3 | 1/3 | 1/4 | 1/3 | 5/8 |
| ConstipationGastrointestinal disorders | 2/3 | 0/3 | 1/4 | 0/3 | 2/8 |
| Dry mouthGastrointestinal disorders | 1/3 | 0/3 | 0/4 | 2/3 | 0/8 |
| PyrexiaGeneral disorders | 2/3 | 1/3 | 1/4 | 0/3 | 2/8 |
| Oedema peripheralGeneral disorders | 2/3 | 0/3 | 0/4 | 0/3 | 2/8 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/3 | 0/3 | 0/4 | 1/3 | 1/8 |
| HypernatremiaMetabolism and nutrition disorders | 0/3 | 0/3 | 0/4 | 2/3 | 0/8 |
| RashSkin and subcutaneous tissue disorders | 0/3 | 2/3 | 1/4 | 2/3 | 1/8 |
The baseline analysis population included all participants that were enrolled into one of the 5 treatment groups.
| Age, Continuous(years) | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 58 ± 20.4 | 55 ± 13.6 | 48 ± 13.8 | 61 ± 17.1 | 60 ± 8.2 | 56.7 ± 12.7 |
| Sex: Female, Male(Participants) | rhuMAb 2C4: 0.5 mg/kg | rhuMAb 2C4: 2 mg/kg | rhuMAb 2C4: 5 mg/kg | rhuMAb 2C4: 10 mg/kg | rhuMAb 2C4: 15 mg/kg | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 0 | 6 | 12 |
| Male | 1 | 2 | 1 | 3 | 2 | 9 |
The record gives a start of Nov 2001, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 11 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab